Multislice computed tomography assessment of everolimus-eluting Absorb bioresorbable scaffolds in comparison with metallic drug-eluting stents from the ABSORB Japan randomised trial
EuroIntervention 2018;14:e1020-e1028 published online November 2017 published online e-edition October 2018. DOI: 10.4244/EIJ-D-17-00716
Kengo Tanabe1*, MD; Jeffrey J. Popma2, MD; Ken Kozuma3, MD; Shigeru Saito4, MD; Toshiya Muramatsu5, MD; Sunao Nakamura6, MD; Atsuo Namiki7, MD; Yoshihiro Morino8, MD; Nobuhisa Hagiwara9, MD; Masaaki Uematsu10, MD; Tomohiro Kawasaki11, MD; Kenshi Fujii12, MD; Patrick W. Serruys13, MD; Yoshinobu Onuma13, MD; Shihwa Ying14, MS; Hajime Kusano14, PhD; Gregg W. Stone15, MD; Takeshi Kimura16, MD; on behalf of the ABSORB Japan Investigators
1. Mitsui Memorial Hospital, Tokyo, Japan; 2. Beth Israel Deaconess Medical Center, Boston, MA, USA; 3. Teikyo University Hospital, Tokyo, Japan; 4. Shonan Kamakura General Hospital, Kanagawa, Japan; 5. Tokyo General Hospital, Tokyo, Japan; 6. Shin-Tokyo
Aims: Blooming artefacts limit accurate coronary assessment by multislice computed tomography (MSCT) in metallic stents. We sought to investigate whether bioresorbable vascular scaffolds
